Friday, February 22, 2013 9:41:05 AM
12:30 PM 2/21/2013 - Business Wire
DUBLIN--(BUSINESS WIRE)--Feb. 21, 2013-- ICONplc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the appointment of Professor William Hall as a non-executive director.
A renowned expert in infectious diseases and virology, Professor Hall is Chair of Medical Microbiology and Director of the Centre for Research in Infectious Diseases at University College Dublin’s (UCD) School of Medicine and Medical Science. He is also a director of UCD’s National Virus Reference Laboratory and is a consultant microbiologist at St. Vincent’s University Hospital Dublin. Professor Hall also serves as a consultant to the Minister of Heath and Children in the Republic of Ireland, providing input on a number of topics including influenza pandemic preparedness and bioterrorism.
Prior to his tenure at UCD, Professor Hall was Professor and Head of the Laboratory of Medical Virology, Senior Physician and Director of the Clinical Research Centre at the Rockefeller University in New York. He has also served as an Assistant and Associate Professor of Medicine at Cornell University.
Professor Hall is a board member of The Atlantic Philanthropies and is a co-founder of the Global Virus Network.
“We are delighted to welcome Professor Hall to the ICON Board,” commented Chairman, Mr. Thomas Lynch. “His knowledge and expertise in virology and infectious diseases, coupled with his international research collaborations in these fields will complement the strengths and talents of our existing board members.”
The information contained in this release is as of 21stFebruary 2013. The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. A description of risks and uncertainties relating to ICON and its business can be found in ICON’s Annual Report for the fiscal year ended December 31, 2011 and in the forms filed with the US Securities and Exchange Commission, including the Forms 20-F, F-1, S-8 and F-3. ICON disclaims any intent or obligation to update these forward-looking statements.
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 79 locations in 37 countries and has approximately 10,045 employees. Further information is available at www.iconplc.com.
Source: ICON plc
ICON/ICLR-F
Source: ICON plc
ICON plc
Investor Relations 1-888-381-7923
or
Brendan Brennan Chief Financial Officer
+ 353 –1-291-2000
or
Sam Farthing VP Investor Relations
+ 353 –1-291-2000
or
Simon Holmes EVP Investor Relations and Corporate Development
+ 353 –1-291-2000
Recent ICLR News
- ICON Announces Pricing of USD 2 Billion Notes • Business Wire • 04/30/2024 08:55:00 PM
- ICON Reports First Quarter 2024 Results • Business Wire • 04/24/2024 08:15:00 PM
- ICON Announces CFO Transition • Business Wire • 04/03/2024 08:15:00 PM
- ICON plc Schedules First Quarter 2024 Earnings Conference Call • Business Wire • 03/25/2024 08:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:37:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 11:10:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:38:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:25:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:16:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:05:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 09:31:28 PM
- ICON plc to Present at Upcoming Investor Conferences • Business Wire • 02/26/2024 09:15:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:14:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/26/2024 09:13:36 PM
- ICON Reports Fourth Quarter and Full Year 2023 Results • Business Wire • 02/21/2024 09:15:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/30/2024 05:11:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/30/2024 11:15:06 AM
- ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call • Business Wire • 01/30/2024 11:00:00 AM
- New ICON Survey Highlights Importance of Combination Therapies in Future Obesity Treatment • Business Wire • 01/24/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:15:06 PM
- ICON Issues Financial Guidance for Full Year 2024 • Business Wire • 01/09/2024 01:00:00 PM
- Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON • Business Wire • 01/08/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/04/2024 12:15:31 PM
- ICON plc to Present at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/04/2024 12:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM